Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
SEER
SEER, INC.
NASDAQ
$2.19
▲ UP 0.92% (0.02)

KEY STATISTICS

Market Cap$119.31 M
52w High$2.41
52w Low$1.55
Dividend Yield—
Frequency—
P/E-1.77
Volume204.20K
Shares Out.54.98M

COMPANY

LEADERSHIP

Omid C. Farokhzad
CHIEF EXECUTIVE
Omid C. Farokhzad

COMPENSATION 2026

Salary$619,208
Stock Awards$937,452
Incentive Plan Pay$397,174
All Other Comp.$173,192
Total$3,549,950

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 4, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
124

PRICE TARGET

Target High$4.00
Target Low$4.00
Target Median$4.00
Target Consensus$4.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$4.15M
NOV
5
THU

ETFS HOLDING THIS STOCK

ETFS HOLDING
23
LISTED HERE
7
RANKED BY POSITION SIZE
VTS.AX
0.00%
1.2M
IWC
0.02%
132.8K
BUSM
0.12%
65.6K
AVSC
0.00%
61.5K
DFMC
0.00%
37.8K
PRFZ
0.00%
23.1K
TYNE
0.53%
1.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
44.52%
HOLDERS
82
TOP 8 OF 82 · RANKED BY POSITION SIZE
Softbank Group Corp.
5.1M sh
$8.63M
Sb Global Advisers Ltd
5.1M sh
$29.79M
Siren, L.L.C.
4.0M sh
$8.68M
Blackrock Inc.
2.6M sh
$4.44M
Vanguard Group Inc
2.2M sh
$4.82M
Acadian Asset Management LLC
2.1M sh
$4.65M
Blackrock, Inc.
1.9M sh
$4.02M
Tang Capital Management LLC
1.3M sh
$2.92M

PRICE

$2.19 ▲ UP 0.92% (+$0.02)
$2.16$2.20$2.249:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.19

About Seer, Inc.

https://seer.bio ↗

Seer, Inc. develops the Proteograph Product Suite to enable proteomic research for academia and biotech firms, collaborating with Discovery Life Sciences and Salk Institute, and is based in Redwood City, CA.

INDUSTRY

Biotechnology

A PRODUCT SEER, INC. IS KNOWN FOR

Proteograph Product Suite with Proteograph ONE Assay and SP200 Automation Instrument
Proteograph Product Suite with Proteograph ONE Assay and SP200 Automation Instrument

Seer's Proteograph Product Suite, launched in May 2025, offers high-throughput, scalable proteomic analysis with the Proteograph ONE Assay and SP200 Automation Instrument, enabling biomarker discovery and personalized medicine insights.

COMPETITORS

COMPETITOR
A COMPARE
BIO COMPARE
NAUT COMPARE
QTRX COMPARE
TMO COMPARE

Seer in 2025

SENTIMENT: + POSITIVE
Sang-Won Lee
PARTNERSHIP · JUNE 2025

Seer Launches Landmark 20,000-Sample Cancer Study with Korea University, Leveraging New High-Throughput Proteomics Platform

In June 2025, Seer announced a major collaboration with Korea University to conduct a population-scale proteomics study of 20,000 plasma samples. The study aims to identify novel blood-based biomarkers for developing AI-driven cancer diagnostics in young adults, representing a significant validation and application of Seer's newly launched Proteograph ONE Assay and SP200 Automation Instrument.

PRODUCT LAUNCH · Q2 2025 · COMPLETED

Seer Launches Transformative High-Throughput Proteomics Platform to Enable Population-Scale Studies

In a pivotal move to accelerate the adoption of large-scale proteomics, Seer, Inc. launched its new high-throughput Proteograph ONE assay and SP200 automation instrument in the second quarter of 2025. This strategic product launch is designed to more than double sample throughput and significantly increase the scale and efficiency of its platform, positioning the company to power major population-scale studies.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book5
Overall Score2

SECTORS PEERS

PEERPRICE
KYMR$107.85COMPARE
NRIX$22.27COMPARE
PHVS$30.94COMPARE
MLYS$22.16COMPARE
ORIC$11.83COMPARE
CGEM$15.54COMPARE
GLUE$10.17COMPARE
SANA$2.76COMPARE

INSIDER TRADES

★
OFFICER: PRESIDENT & CFO
Horn David R.
Sale · 7.3K shares
2026-08-18
★
DIRECTOR
Gulyani Meeta
Purchase · 25.0K shares
2026-07-28
★
DIRECTOR
Gulyani Meeta
Purchase · 16.5K shares
2026-07-28
★
DIRECTOR
LANGER ROBERT
Purchase · 25.0K shares
2026-07-28